BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 15676215)

  • 1. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
    Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
    Parra C; Roldán E; Rodríguez C; Pérez de Oteyza J; Oteho E; López J; Maldonado MS; García Laraña J; Muñoz A; Odriozola J; Brieva JA
    Med Clin (Barc); 1999 Jun; 113(1):1-5. PubMed ID: 10422068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
    Ericson SG; Colby E; Welch L; Ball ED
    Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
    Newman A; Clutterbuck RD; DeLord C; Powles RL; Catovsky D; Millar JL
    J Investig Med; 1995 Jun; 43(3):269-74. PubMed ID: 7614073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryopreservation of human bone marrow after purging T-cells or tumor cells.
    Zhang ZX; Xu YJ; Chen Y; Li Y; Shen BF; Bai Y
    Cryobiology; 1994 Oct; 31(5):478-82. PubMed ID: 7988157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
    Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
    Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J
    Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.
    Passos-Coelho J; Ross AA; Davis JM; Huelskamp AM; Clarke B; Noga SJ; Davidson NE; Kennedy MJ
    Cancer Res; 1994 May; 54(9):2366-71. PubMed ID: 8162582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.
    Beaujean F; Bernaudin F; Kuentz M; Lemerle S; Cordonnier C; Le Forestier C; Reinert P; Duedari N; Brandely M; Vernant JP
    Bone Marrow Transplant; 1995 May; 15(5):691-6. PubMed ID: 7670397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT.
    Bassan R; Cortelazzo S; Rambaldi A; Cornelli P; Borleri G; Bellavita P; Biondi A; Barbui T
    Bone Marrow Transplant; 1995 May; 15(5):791-3. PubMed ID: 7670409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients.
    Vavassori M; Maccario R; Moretta A; Comoli P; Wack A; Locatelli F; Lanzavecchia A; Maserati E; Dellabona P; Casorati G; Montagna D
    J Immunol; 1996 Dec; 157(12):5739-47. PubMed ID: 8955228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ex-vivo treatment of a bone marrow graft].
    Bieva CJ
    Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
    Lopez M; Mary JY; Sainteny F
    Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
    Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
    Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.